序号 |
标题 |
次数 |
作者 |
发布时间 |
76816 |
(HO)2-PO-S-(CH2)m-COONHS 硫-(2,5-二氧代 - 吡咯烷-1-基氧基羰基)-1-基硫代磷酸 |
122 |
h |
2024-12-19 |
76817 |
2529982-76-9,Azido-PEG4-Val-Ala-PAB,叠氮-四聚乙二醇-VAL-ALA-PAB |
136 |
kx |
2024-12-19 |
76818 |
Au_12_C11EG6 金团簇12-直链烷烃六聚乙二醇 |
156 |
h |
2024-12-19 |
76819 |
cas:863971-17-9 ,MC-Val-Cit-PAB-MMAF,MC-VAL-CIT-PAB-MMAF游离态 |
101 |
kx |
2024-12-19 |
76820 |
CF3-(CF2)5-C2-O-C11-Si(OMe)3 巯基-直链烷烃连接氟化硫醇和硅烷 |
127 |
h |
2024-12-19 |
76821 |
cas:2353409-69-3 , Mal-PEG8-Val-Cit-PAB-MMAE,马来酰亚胺-八聚乙二醇-VAL-CIT-PAB-MMAE |
112 |
kx |
2024-12-19 |
76822 |
cas:2129164-91-4 , DBCO-PEG4-Val-Cit-PAB-MMAE,二苯并环辛炔-四聚乙二醇-VAL-CIT-PAB-MMAE |
167 |
kx |
2024-12-19 |
76823 |
MAL-di-EG-Val-Cit-PAB-MMAF,由ADC连接桥(MAL-di-EG-Val-Cit-PAB)和有效的微管蛋白聚合阻断剂(MMAF, Monomethyl auristatin F)组成 |
135 |
WYQ |
2024-12-19 |
76824 |
MAL-di-EG-Val-Cit-PAB-MMAE,CAS编号:2746391-62-6 |
141 |
WYQ |
2024-12-19 |
76825 |
cas:644981-35-1 , Val-Cit-PAB-MMAE, ADC试剂 |
86 |
kx |
2024-12-19 |
76826 |
cas:2754384-60-4,DBCO-(PEG)3-VC-PAB-MMAE,抗体药物偶联物(ADC) |
167 |
kx |
2024-12-19 |
76827 |
AcLys-PABC-VC-Aur0101(CAS:1438851-17-2) |
121 |
WYQ |
2024-12-19 |
76828 |
反式环辛烯-MMAE,TCO-MMAE, ADC试剂 |
159 |
kx |
2024-12-19 |
76829 |
Hydrazone-doxorubicin,阿霉素-腙键偶联物 |
213 |
WYQ |
2024-12-19 |
76830 |
SPP-DM1(CAS号:452072-20-7)C44H59ClN4O14S2 |
175 |
WYQ |
2024-12-19 |
76831 |
氨基-二聚乙二醇-VG-N-双(一聚乙二醇-叠氮),Amino-PEG2-VG-N-Bis(PEG1-azide) |
96 |
kx |
2024-12-19 |
76832 |
DOTA-NHS ester,羟基琥珀酰亚胺-四氮杂环十二烷四乙酸(CAS号:170908-81-3) |
118 |
WYQ |
2024-12-19 |
76833 |
Maleimido-mono-amide-DOTA(CAS号:1006711-90-5) |
177 |
WYQ |
2024-12-19 |
76834 |
cas:2055041-40-0,Azido-PEG1-Val-Cit-PAB-OH,叠氮-一聚乙二醇-VAL-CIT-PAB-羟基 |
84 |
kx |
2024-12-19 |
76835 |
MB-VC-MGBA CAS号:932744-62-2 |
148 |
WYQ |
2024-12-19 |
76836 |
Anti-GPNMB-VC-MMAE-ADC抗体偶联药物 |
108 |
zyl |
2024-12-19 |
76837 |
MA-PEG8-VA-PAB-SG3199,硫醇反应SET™毒素 |
158 |
WYQ |
2024-12-19 |
76838 |
cas:1662687-83-3 , Mal-PEG2-Val-Cit-PABA,马来酰亚胺-二聚乙二醇-VAL-CIT-PABA |
96 |
kx |
2024-12-19 |
76839 |
Boc-Val-Ala-PAB cas:1884577-99-4 |
123 |
zyl |
2024-12-19 |
76840 |
perfluorophenyl 1-(cyclooct-2-ynyloxy)-2-oxo-6,9,12-trioxa-3-azapentadecan-15-oate |
91 |
wyh |
2024-12-19 |
76841 |
MA-PEG4-VA-PBD(CAS号:2259318-50-6) |
126 |
WYQ |
2024-12-19 |
76842 |
SPDP-Val-Cit-PAB-PNP-ADC抗体偶联药物 |
162 |
zyl |
2024-12-19 |
76843 |
cas:1438853-35-0,Mal-PEG3-Val-Cit-PAB-PNP,马来酰亚胺-三聚乙二醇-VAL-CIT-PAB-PNP 酯 |
100 |
kx |
2024-12-19 |
76844 |
Mc-vc-PABC-SP 141,一种用于抗体药物偶联物(ADC)合成的linker或连接臂 |
117 |
WYQ |
2024-12-19 |
76845 |
perfluorophenyl 1-(1,3-dioxoisoindolin-2-yloxy)-3,6,9,12-tetraoxapentadecan-15-oate |
133 |
wyh |
2024-12-19 |
76846 |
cas:2055041-37-5,Mal-PEG1-Val-Cit-PAB-OH,马来酰亚胺-一聚乙二醇-VAL-CIT-PAB-羟基 |
124 |
kx |
2024-12-19 |
76847 |
perfluorophenyl 15-(2,5-dioxo-2H-pyrrol-1(5H)-yl)-13-oxo-3,6,9-trioxa-12-azapentadecan-1-oate |
106 |
wyh |
2024-12-19 |
76848 |
MC-Val-Cit-PAB-PNP cas:159857-81-5 |
113 |
zyl |
2024-12-19 |
76849 |
NAMPT-linker(CAS号:2241019-57-6) |
104 |
WYQ |
2024-12-19 |
76850 |
cas:103848-61-9,6-Maleimidocaproic acid sulfo-NHS |
115 |
wyh |
2024-12-19 |
76851 |
cas:159857-80-4 ,MC-Val-Cit-PAB-OH, ADC(抗体偶联药物 ) |
116 |
kx |
2024-12-19 |
76852 |
Boc-Val-Cit cas:870487-08-4 |
143 |
zyl |
2024-12-19 |
76853 |
cas:663598-66-1,1-((4-((5-Nitropyridin-2-yl)disulfanyl)pentanoyl)oxy)-2,5-dioxopyrrolidine-3-sulfonic acid |
113 |
wyh |
2024-12-19 |
76854 |
cas:870487-10-8,Boc-Val-Cit-PAB-PNP,BOC-VAL-CIT-PAB-PNP 酯 |
105 |
kx |
2024-12-19 |
76855 |
cas:2353409-69-3 Mal-PEG8-Val-Cit-PAB-MMAE |
160 |
zyl |
2024-12-19 |
76856 |
cas:108852-90-0 Nemorubicin 奈莫柔比星 |
136 |
zyl |
2024-12-19 |
76857 |
cas:159858-22-7 , Fmoc-Val-Cit-PAB-OH,ADC(抗体偶联药物) |
105 |
kx |
2024-12-19 |
76858 |
cas:1626359-59-8 磺基-SPDB-DM4 |
92 |
zyl |
2024-12-19 |
76859 |
cas:870487-09-5,Boc-Val-Cit-PAB, ADC试剂 |
83 |
kx |
2024-12-19 |
76860 |
NH2-Glu-Gly-Cit-PAB-OH, ADC试剂 |
161 |
kx |
2024-12-19 |